Literature DB >> 21296036

Distribution of CFTR mutations in Eastern Hungarians: relevance to genetic testing and to the introduction of newborn screening for cystic fibrosis.

Gergely Ivady1, Laszlo Madar, Bela Nagy, Ferenc Gonczi, Eva Ajzner, Erika Dzsudzsak, Lenka Dvořáková, Eva Gombos, Janos Kappelmayer, Milan Macek, Istvan Balogh.   

Abstract

BACKGROUND: The aim of this study was characterization of an updated distribution of CFTR mutations in a representative cohort of 40 CF patients with the classical form of the disease drawn from Eastern Hungary. Due to the homogeneity of the Hungarian population our data are generally applicable to other regions of the country, including the sizeable diaspora.
METHODS: We utilized the recommended "cascade" CFTR mutation screening approach, initially using a commercial assay, followed by examination of the common "Slavic" deletion CFTRdele2,3(21kb). Subsequently, the entire CFTR coding region of the CFTR gene was sequenced in patients with yet unidentified mutations.
RESULTS: The Elucigene CF29(Tm) v2 assay detected 81.25% of all CF causing mutations. An addition of the CFTRdele2,3(21kb) increased the mutation detection rate to 86.25%. DNA sequencing enabled us to identify mutations on 79/80 CF alleles. Mutations [CFTRdele2,3(21kb), p.Gln685ThrfsX4 (2184insA) were found at an unusually high frequency, each comprising 5.00% of all CF alleles.
CONCLUSION: We have identified common CF causing mutations in the Hungarian population with the most common mutations (p.Phe508del, p.Asn1303Lys, CFTRdele2,3(21kb), 2184insA, p.Gly542X, and p.Leu101X), comprising over 93.75% of all CF alleles. Obtained data are applicable to the improvement of DNA diagnostics in Hungary and beyond, and are the necessary prerequisite for the introduction of a nationwide "two tier" CF newborn screening program.
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21296036     DOI: 10.1016/j.jcf.2010.12.009

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  4 in total

1.  Mutational spectrum of smith-lemli-opitz syndrome patients in hungary.

Authors:  I Balogh; K Koczok; G P Szabó; O Török; K Hadzsiev; G Csábi; L Balogh; E Dzsudzsák; E Ajzner; L Szabó; V Csákváry; A V Oláh
Journal:  Mol Syndromol       Date:  2012-11-09

2.  Molecular Analysis of Cystic Fibrosis Patients in Hungary - An Update to the Mutational Spectrum.

Authors:  Gergely Ivády; Katalin Koczok; Laszlo Madar; Eva Gombos; Izabella Toth; Klaudia Gyori; István Balogh
Journal:  J Med Biochem       Date:  2014-10-08       Impact factor: 3.402

3.  Analytical parameters and validation of homopolymer detection in a pyrosequencing-based next generation sequencing system.

Authors:  Gergely Ivády; László Madar; Erika Dzsudzsák; Katalin Koczok; János Kappelmayer; Veronika Krulisova; Milan Macek; Attila Horváth; István Balogh
Journal:  BMC Genomics       Date:  2018-02-21       Impact factor: 3.969

4.  CFTR mutations spectrum and the efficiency of molecular diagnostics in Polish cystic fibrosis patients.

Authors:  Ewa Ziętkiewicz; Ewa Rutkiewicz; Andrzej Pogorzelski; Barbara Klimek; Katarzyna Voelkel; Michał Witt
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.